Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan for Sarcoidosis Associated Pulmonary Hypertension
NCT00581607Phase 3Completed
- Sponsor
- University of Cincinnati
- Start
- Apr 2008
- Primary completion
- Oct 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by University of Cincinnati. Primary endpoint: Six-Minute Walk Distance at 16 weeks. Started Apr 2008; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00581607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581607.